Clinical trials
Acute HIV Infection clinical trials
Below are recruiting acute hiv infection clinical trials, each written for real people, not researchers. We’re tracking 65 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04883255RecruitingEarly Phase 1
Study cannabis effects on brain function in adults with HIV
This early-phase study looks at how cannabis (and the body’s cannabinoid system) may affect thinking and brain-related measures in people with HIV. You may be asked to avoid cannabis and complete several brain and health assessments to see how these factors relate.
San Diego, CaliforniaAges 18–65 - NCT06554717RecruitingPhase 2
Tesamorelin and exercise for physical function in HIV
This study tests whether adding tesamorelin to an exercise program helps older adults with HIV improve their physical function and reduce belly fat. It is designed for people who are mostly sedentary and show early signs of frailty.
Aurora, ColoradoAges 50–80 - NCT07717372Recruiting
CRP test for adults with respiratory infection in primary care
This trial tests whether a simple finger-prick test (C-reactive protein or CRP) can help doctors decide whether antibiotics are needed for adults with a cold or other respiratory infection. If you are an adult with recent symptoms and have not taken antibiotics yet, you may be able to join.
JakartaAges 18 years+ - NCT05488431RecruitingPhase 2
Bempedoic acid to lower cholesterol and inflammation in HIV
This Phase 2 trial studies whether bempedoic acid can lower cholesterol and inflammation in people with HIV who are already on effective HIV medications. It may help reduce signs of artery inflammation that can contribute to heart and stroke risk.
Los Angeles, CaliforniaAges 40 years+ - NCT07202546RecruitingPhase 2
New oral HIV drug trial for people new to treatment
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
Bakersfield, CaliforniaAges 18 years+ - NCT07342491RecruitingPhase 1
Testing dasatinib to shrink HIV reservoir
This trial tests whether the drug dasatinib can reduce the hidden HIV reservoir in people who have had their virus well-controlled on HIV medications for a long time. It may help move toward a cure by targeting the cells where HIV hides.
Chicago, IllinoisAges 18 years+ - NCT05897099Recruiting
Telehealth harm-reduction for people at HIV risk
This study tests whether a telehealth program can reduce harm and lower HIV risk by helping with safer syringe use. It may help if you have recent syringe exchange use and are not currently on HIV prevention pills.
Miami, FloridaAges 18 years+ - NCT05419024RecruitingPhase 2
Imaging and biopsy during a planned HIV treatment pause
This Phase 2 study uses special scans (PET/CT) and tissue sampling (biopsy) to learn what is happening in the body while people with HIV take a planned break from antiretroviral therapy (ART) for up to 90 days. It may help researchers find better ways to control HIV without ongoing treatment, though joining involves careful monitoring during the pause.
Bethesda, MarylandAges 18–100 - NCT05187429RecruitingPhase 1/Phase 2
Low-dose nivolumab for adults with HIV on stable therapy
This trial tests whether a low dose of nivolumab can safely affect the immune system in adults living with HIV who are already on stable HIV treatment. You may benefit by helping researchers understand a new approach, but the main goal is to check safety and early effectiveness.
Melbourne, VictoriaAges 18–65 - NCT07682961RecruitingPhase 3
Study of new HIV injection vs. standard injectables
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
Fort Lauderdale, FloridaAges 18 years+ - NCT06205602RecruitingPhase 2
HIV treatment with antibodies for a cure in Africa
This study tests if giving antibodies along with standard HIV medications can help control the virus without daily pills. It may lead to a functional cure for people living with HIV.
GaboroneAges 18–60 - NCT07683000RecruitingPhase 3
Study of three HIV drugs for adults with controlled HIV
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
Berkeley, MichiganAges 18 years+ - NCT06807736Recruiting
Choosing injectable PrEP for HIV prevention in Cape Town
This study offers three ways to prevent HIV: a shot every two months (injectable PrEP), daily pills, or a vaginal ring. Researchers in Cape Town will help you choose the option that fits your life best.
Cape Town, Western ProvinceAges 15 years+ - NCT05077527RecruitingPhase 1
CAR-T treatment for HIV and aggressive B-cell lymphoma
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
Duarte, CaliforniaAges 18 years+ - NCT04052022Recruiting
Study of TB flare-ups in people without HIV
This study looks at why some people with tuberculosis (TB) get worse or develop new inflammation after they initially start improving on treatment—called a “paradoxical reaction.” It collects blood and tissue samples to better understand these flare-ups and guide future care.
Bethesda, MarylandAges 18–99 - NCT05418868RecruitingPhase 1
Long-acting cabotegravir injection safety in healthy adults
This Phase 1 study tests how the body handles a long-acting (slow-release) cabotegravir injection combined with a drug called hyaluronidase. It also checks safety and side effects in healthy adults to help future HIV-prevention or treatment plans.
Orlando, FloridaAges 18–55 - NCT05674656RecruitingPhase 1/Phase 2
Testing dolutegravir and rilpivirine in HIV-positive children
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
Long Beach, CaliforniaAges 6–12 - NCT05758246RecruitingPhase 2
Fisetin to slow worsening of sepsis in older hospital patients
This Phase 2 trial tests whether a drug called fisetin can slow the progression of sepsis once you are admitted to the hospital. It may help patients recover more quickly or avoid worsening, but eligibility depends on how severe the illness is and what other treatments you need.
Gainesville, FloridaAges 65 years+ - NCT06281834RecruitingPhase 1
Dolutegravir levels with TB prevention in children
This study tests how dolutegravir (an HIV medicine) works in children when taken with weekly rifapentine and isoniazid (medicines to prevent tuberculosis). It may help find the right dose for kids who have HIV and are at risk for TB.
Ibadan, Oyo StateAges 4 weeks–11 years - NCT07031063RecruitingPhase 4
HIV treatment study for people starting therapy
This study compares two HIV medications (DTG/3TC and BIC/TAF/FTC) to see which works better and is safer for people who have never taken HIV treatment before. It may help you find a once-daily pill that controls the virus and has fewer side effects.
Mexico City, AzcapotzalcoAges 18 years+ - NCT07636928RecruitingPhase 1
Study of how the body absorbs a new HIV medicine
This early-stage study tests a new HIV medication (VH4524184) to understand how your body absorbs and processes it. You'll take a single dose of the medication with a small amount of radioactive tracer, which helps researchers track where the drug goes in your body.
GroningenAges 18–55 - NCT06646562RecruitingPhase 4
Long-acting injectable HIV meds for adults 60 and older
This study tests whether two long-acting injectable HIV medications (cabotegravir and rilpivirine) can keep the virus under control in people aged 60 and older. It aims to offer a convenient alternative to daily pills for older adults with HIV.
Elche, AlicanteAges 60 years+ - NCT05985642Recruiting
HIV treatment interruption study for long-term participants
This study looks at people with HIV who have already taken a break from their HIV medications (called an analytic treatment interruption, or ATI) as part of another study. It aims to understand how well the body can control the virus during longer breaks from treatment, up to 96 weeks.
San Francisco, CaliforniaAges 18 years+ - NCT06684379RecruitingPhase 1/Phase 2
Two Doses of PRS CK STORM for Severe Viral Pneumonia
This study tests a new drug called PRS CK STORM to see if it can safely calm the body's overactive immune response (cytokine storm) in people with severe pneumonia from COVID-19, flu, or RSV who need oxygen. It aims to reduce inflammation and improve recovery.
Alcalá de Henares, MadridAges 18 years+
Hear when a new Acute HIV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute hiv infection?
- Yes. Clin2 currently lists 65 recruiting acute hiv infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute hiv infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute hiv infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.